Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development
Identifieur interne : 000790 ( PascalFrancis/Corpus ); précédent : 000789; suivant : 000791Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development
Auteurs : Wai-Yan Choy ; Shu-Guang Lin ; Paul Kay-Sheung Chan ; John Siu-Lun Tam ; Y. M. Dennis Lo ; Ida Miu-Ting Chu ; Sau-Na Tsai ; Ming-Qi Zhong ; Kwok-Pui Fung ; Mary Miu-Yee Waye ; Stephen Kwok-Wing Tsui ; Kai-On Ng ; Zhi-Xin Shan ; MIN YANG ; Yi-Long Wu ; Zhan-Yi Lin ; Sai-Ming NgaiSource :
- Clinical chemistry : (Baltimore, Md.) [ 0009-9147 ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 04-0547697 INIST |
---|---|
ET : | Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development |
AU : | CHOY (Wai-Yan); LIN (Shu-Guang); CHAN (Paul Kay-Sheung); TAM (John Siu-Lun); LO (Y. M. Dennis); CHU (Ida Miu-Ting); TSAI (Sau-Na); ZHONG (Ming-Qi); FUNG (Kwok-Pui); WAYE (Mary Miu-Yee); TSUI (Stephen Kwok-Wing); NG (Kai-On); SHAN (Zhi-Xin); MIN YANG; WU (Yi-Long); LIN (Zhan-Yi); NGAI (Sai-Ming) |
AF : | Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong/Shatin/Hong-Kong (1 aut., 8 aut., 17 aut.); Research Center of Medical Sciences, Guangdong Provincial People's Hospital/Guangdong/Chine (2 aut., 13 aut., 14 aut., 15 aut., 16 aut.); Department of Microbiology, The Chinese University of Hong Kong/Shatin/Hong-Kong (3 aut., 4 aut., 6 aut.); Department of Chemical Pathology, The Chinese University of Hong Kong/Shatin/Hong-Kong (5 aut., 12 aut.); Department of Biology, The Chinese University of Hong Kong/Shatin/Hong-Kong (7 aut., 17 aut.); Department of Biochemistry, The Chinese University of Hong Kong/Shatin/Hong-Kong (9 aut., 10 aut., 11 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Clinical chemistry : (Baltimore, Md.); ISSN 0009-9147; Coden CLCHAU; Etats-Unis; Da. 2004; Vol. 50; No. 6; Pp. 1036-1042; Bibl. 16 ref. |
LA : | Anglais |
EA : | Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach. |
CC : | 002B24; 002A02; 002A03 |
FD : | Produit synthétique; Peptide; Syndrome respiratoire aigu sévère; Coronavirus; Glycoprotéine; Vaccin; Immunoprophylaxie; Prévention; Développement; Biochimie; Biologie clinique; Biologie moléculaire |
FG : | Virose; Infection; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Poumon pathologie |
ED : | Synthetic product; Peptides; Severe acute respiratory syndrome; Coronavirus; Glycoprotein; Vaccine; Immunoprophylaxis; Prevention; Development; Biochemistry; Clinical biology; Molecular biology |
EG : | Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease |
SD : | Producto sintético; Péptido; Síndrome respiratorio agudo severo; Coronavirus; Glicoproteína; Vacuna; Inmunoprofilaxia; Prevención; Desarrollo; Bioquímica; Biología clínica; Biología molecular |
LO : | INIST-7603.354000113605350080 |
ID : | 04-0547697 |
Links to Exploration step
Pascal:04-0547697Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development</title>
<author><name sortKey="Choy, Wai Yan" sort="Choy, Wai Yan" uniqKey="Choy W" first="Wai-Yan" last="Choy">Wai-Yan Choy</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Shu Guang" sort="Lin, Shu Guang" uniqKey="Lin S" first="Shu-Guang" last="Lin">Shu-Guang Lin</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Paul Kay Sheung" sort="Chan, Paul Kay Sheung" uniqKey="Chan P" first="Paul Kay-Sheung" last="Chan">Paul Kay-Sheung Chan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tam, John Siu Lun" sort="Tam, John Siu Lun" uniqKey="Tam J" first="John Siu-Lun" last="Tam">John Siu-Lun Tam</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lo, Y M Dennis" sort="Lo, Y M Dennis" uniqKey="Lo Y" first="Y. M. Dennis" last="Lo">Y. M. Dennis Lo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemical Pathology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chu, Ida Miu Ting" sort="Chu, Ida Miu Ting" uniqKey="Chu I" first="Ida Miu-Ting" last="Chu">Ida Miu-Ting Chu</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsai, Sau Na" sort="Tsai, Sau Na" uniqKey="Tsai S" first="Sau-Na" last="Tsai">Sau-Na Tsai</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Biology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>7 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhong, Ming Qi" sort="Zhong, Ming Qi" uniqKey="Zhong M" first="Ming-Qi" last="Zhong">Ming-Qi Zhong</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fung, Kwok Pui" sort="Fung, Kwok Pui" uniqKey="Fung K" first="Kwok-Pui" last="Fung">Kwok-Pui Fung</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Waye, Mary Miu Yee" sort="Waye, Mary Miu Yee" uniqKey="Waye M" first="Mary Miu-Yee" last="Waye">Mary Miu-Yee Waye</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsui, Stephen Kwok Wing" sort="Tsui, Stephen Kwok Wing" uniqKey="Tsui S" first="Stephen Kwok-Wing" last="Tsui">Stephen Kwok-Wing Tsui</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Kai On" sort="Ng, Kai On" uniqKey="Ng K" first="Kai-On" last="Ng">Kai-On Ng</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemical Pathology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shan, Zhi Xin" sort="Shan, Zhi Xin" uniqKey="Shan Z" first="Zhi-Xin" last="Shan">Zhi-Xin Shan</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Yang" sort="Min Yang" uniqKey="Min Yang" last="Min Yang">MIN YANG</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wu, Yi Long" sort="Wu, Yi Long" uniqKey="Wu Y" first="Yi-Long" last="Wu">Yi-Long Wu</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Zhan Yi" sort="Lin, Zhan Yi" uniqKey="Lin Z" first="Zhan-Yi" last="Lin">Zhan-Yi Lin</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ngai, Sai Ming" sort="Ngai, Sai Ming" uniqKey="Ngai S" first="Sai-Ming" last="Ngai">Sai-Ming Ngai</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Biology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>7 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0547697</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0547697 INIST</idno>
<idno type="RBID">Pascal:04-0547697</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000790</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development</title>
<author><name sortKey="Choy, Wai Yan" sort="Choy, Wai Yan" uniqKey="Choy W" first="Wai-Yan" last="Choy">Wai-Yan Choy</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Shu Guang" sort="Lin, Shu Guang" uniqKey="Lin S" first="Shu-Guang" last="Lin">Shu-Guang Lin</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Paul Kay Sheung" sort="Chan, Paul Kay Sheung" uniqKey="Chan P" first="Paul Kay-Sheung" last="Chan">Paul Kay-Sheung Chan</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tam, John Siu Lun" sort="Tam, John Siu Lun" uniqKey="Tam J" first="John Siu-Lun" last="Tam">John Siu-Lun Tam</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lo, Y M Dennis" sort="Lo, Y M Dennis" uniqKey="Lo Y" first="Y. M. Dennis" last="Lo">Y. M. Dennis Lo</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemical Pathology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chu, Ida Miu Ting" sort="Chu, Ida Miu Ting" uniqKey="Chu I" first="Ida Miu-Ting" last="Chu">Ida Miu-Ting Chu</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsai, Sau Na" sort="Tsai, Sau Na" uniqKey="Tsai S" first="Sau-Na" last="Tsai">Sau-Na Tsai</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Biology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>7 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zhong, Ming Qi" sort="Zhong, Ming Qi" uniqKey="Zhong M" first="Ming-Qi" last="Zhong">Ming-Qi Zhong</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fung, Kwok Pui" sort="Fung, Kwok Pui" uniqKey="Fung K" first="Kwok-Pui" last="Fung">Kwok-Pui Fung</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Waye, Mary Miu Yee" sort="Waye, Mary Miu Yee" uniqKey="Waye M" first="Mary Miu-Yee" last="Waye">Mary Miu-Yee Waye</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tsui, Stephen Kwok Wing" sort="Tsui, Stephen Kwok Wing" uniqKey="Tsui S" first="Stephen Kwok-Wing" last="Tsui">Stephen Kwok-Wing Tsui</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ng, Kai On" sort="Ng, Kai On" uniqKey="Ng K" first="Kai-On" last="Ng">Kai-On Ng</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Chemical Pathology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shan, Zhi Xin" sort="Shan, Zhi Xin" uniqKey="Shan Z" first="Zhi-Xin" last="Shan">Zhi-Xin Shan</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Yang" sort="Min Yang" uniqKey="Min Yang" last="Min Yang">MIN YANG</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wu, Yi Long" sort="Wu, Yi Long" uniqKey="Wu Y" first="Yi-Long" last="Wu">Yi-Long Wu</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Zhan Yi" sort="Lin, Zhan Yi" uniqKey="Lin Z" first="Zhan-Yi" last="Lin">Zhan-Yi Lin</name>
<affiliation><inist:fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ngai, Sai Ming" sort="Ngai, Sai Ming" uniqKey="Ngai S" first="Sai-Ming" last="Ngai">Sai-Ming Ngai</name>
<affiliation><inist:fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Biology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>7 aut.</sZ>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical chemistry : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Clin. chem. : (Baltim. Md.)</title>
<idno type="ISSN">0009-9147</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biochemistry</term>
<term>Clinical biology</term>
<term>Coronavirus</term>
<term>Development</term>
<term>Glycoprotein</term>
<term>Immunoprophylaxis</term>
<term>Molecular biology</term>
<term>Peptides</term>
<term>Prevention</term>
<term>Severe acute respiratory syndrome</term>
<term>Synthetic product</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Produit synthétique</term>
<term>Peptide</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Glycoprotéine</term>
<term>Vaccin</term>
<term>Immunoprophylaxie</term>
<term>Prévention</term>
<term>Développement</term>
<term>Biochimie</term>
<term>Biologie clinique</term>
<term>Biologie moléculaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-9147</s0>
</fA01>
<fA02 i1="01"><s0>CLCHAU</s0>
</fA02>
<fA03 i2="1"><s0>Clin. chem. : (Baltim. Md.)</s0>
</fA03>
<fA05><s2>50</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHOY (Wai-Yan)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LIN (Shu-Guang)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAN (Paul Kay-Sheung)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TAM (John Siu-Lun)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LO (Y. M. Dennis)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CHU (Ida Miu-Ting)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TSAI (Sau-Na)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ZHONG (Ming-Qi)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>FUNG (Kwok-Pui)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>WAYE (Mary Miu-Yee)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>TSUI (Stephen Kwok-Wing)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>NG (Kai-On)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SHAN (Zhi-Xin)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>MIN YANG</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>WU (Yi-Long)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>LIN (Zhan-Yi)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>NGAI (Sai-Ming)</s1>
</fA11>
<fA14 i1="01"><s1>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Research Center of Medical Sciences, Guangdong Provincial People's Hospital</s1>
<s2>Guangdong</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Microbiology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Chemical Pathology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Biology, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>7 aut.</sZ>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Biochemistry, The Chinese University of Hong Kong</s1>
<s2>Shatin</s2>
<s3>HKG</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>1036-1042</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>7603</s2>
<s5>354000113605350080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0547697</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical chemistry : (Baltimore, Md.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A02</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Produit synthétique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Synthetic product</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Producto sintético</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Peptide</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Peptides</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Péptido</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Glycoprotéine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Glycoprotein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Glicoproteína</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Prévention</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prevention</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Prevención</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Développement</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Development</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Biochimie</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Biochemistry</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Bioquímica</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Biologie clinique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Clinical biology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Biología clínica</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Biologie moléculaire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Molecular biology</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Biología molecular</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>313</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0547697 INIST</NO>
<ET>Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development</ET>
<AU>CHOY (Wai-Yan); LIN (Shu-Guang); CHAN (Paul Kay-Sheung); TAM (John Siu-Lun); LO (Y. M. Dennis); CHU (Ida Miu-Ting); TSAI (Sau-Na); ZHONG (Ming-Qi); FUNG (Kwok-Pui); WAYE (Mary Miu-Yee); TSUI (Stephen Kwok-Wing); NG (Kai-On); SHAN (Zhi-Xin); MIN YANG; WU (Yi-Long); LIN (Zhan-Yi); NGAI (Sai-Ming)</AU>
<AF>Molecular Biotechnology Program, Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong/Shatin/Hong-Kong (1 aut., 8 aut., 17 aut.); Research Center of Medical Sciences, Guangdong Provincial People's Hospital/Guangdong/Chine (2 aut., 13 aut., 14 aut., 15 aut., 16 aut.); Department of Microbiology, The Chinese University of Hong Kong/Shatin/Hong-Kong (3 aut., 4 aut., 6 aut.); Department of Chemical Pathology, The Chinese University of Hong Kong/Shatin/Hong-Kong (5 aut., 12 aut.); Department of Biology, The Chinese University of Hong Kong/Shatin/Hong-Kong (7 aut., 17 aut.); Department of Biochemistry, The Chinese University of Hong Kong/Shatin/Hong-Kong (9 aut., 10 aut., 11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical chemistry : (Baltimore, Md.); ISSN 0009-9147; Coden CLCHAU; Etats-Unis; Da. 2004; Vol. 50; No. 6; Pp. 1036-1042; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788-820) and S6 (residues 1002-1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach.</EA>
<CC>002B24; 002A02; 002A03</CC>
<FD>Produit synthétique; Peptide; Syndrome respiratoire aigu sévère; Coronavirus; Glycoprotéine; Vaccin; Immunoprophylaxie; Prévention; Développement; Biochimie; Biologie clinique; Biologie moléculaire</FD>
<FG>Virose; Infection; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Poumon pathologie</FG>
<ED>Synthetic product; Peptides; Severe acute respiratory syndrome; Coronavirus; Glycoprotein; Vaccine; Immunoprophylaxis; Prevention; Development; Biochemistry; Clinical biology; Molecular biology</ED>
<EG>Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease</EG>
<SD>Producto sintético; Péptido; Síndrome respiratorio agudo severo; Coronavirus; Glicoproteína; Vacuna; Inmunoprofilaxia; Prevención; Desarrollo; Bioquímica; Biología clínica; Biología molecular</SD>
<LO>INIST-7603.354000113605350080</LO>
<ID>04-0547697</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000790 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000790 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:04-0547697 |texte= Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development }}
This area was generated with Dilib version V0.6.33. |